Active substances
Sodium phosphate dibasic + Sodium phosphate monobasic
- US FDA 3
- Health Canada 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE | 0.398GM;1.102GM | tablet · oral | NOVEL LABS INC | Prescription | 30 Dec 2011 |
| VISICOL | 0.398GM;1.102GM | tablet · oral | SALIX PHARMS | Discontinued | 21 Sep 2000 |
| OSMOPREP | 0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | SALIX PHARMS | Discontinued | 16 Mar 2006 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SODIUM PHOSPHATES INJECTION USP | 00896187 | 276 MG / ML; 268 MG / ML | SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.